Abstract
This is a brief summary of the biologic basis for use of CTLA-4 blockade in the treatment of cancer, specifically melanoma and renal cell carcinoma. Included is the biology of CTLA-4, the preclinical and clinical studies to date. Lastly, the future goals and directions of CTLA-4 are discussed including combination with newer immunotherapies.
Author supplied keywords
Cite
CITATION STYLE
APA
Hughes, T., & Kaufman, H. L. (2017). CTLA-4. In Cancer Therapeutic Targets (Vol. 1–2, pp. 157–170). Springer New York. https://doi.org/10.1007/978-1-4419-0717-2_59
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free